Telehealth Giant Absorbs $178M Loss to Secure Eli Lilly Weight Loss Drug Partnership
Hims & Hers pivots from compounded medications to branded GLP-1s, mirroring its Novo Nordisk deal as digital health platforms become pharmaceutical distribution channels.
Hims & Hers Health has announced a partnership with Eli Lilly to distribute branded weight loss medications directly through its telehealth platform, marking the second major pharmaceutical alliance for the company following a similar agreement with Novo Nordisk in March 2025. The deal, announced November 6, 2026, sent Hims & Hers stock up 8% despite the company reporting combined losses of $178 million across the first two quarters of 2026 as it transitions away from compounded GLP-1 drugs.
From Compounding Controversy to Pharmaceutical Partnership
The Eli Lilly agreement provides Hims & Hers customers direct access to Zepbound (tirzepatide injectable) at $299 per month and Foundayo (orforglipron oral) at $149 per month through the platform's integrated care model. These self-pay prices position the medications below typical insurance copays for many patients while bundling 24/7 care team access, nutrition guidance, clinical check-ins, and weight loss community support.
The partnership represents a strategic shift for Hims & Hers, which faced regulatory pressure from the FDA and pharmaceutical manufacturers earlier in 2026. The company backed down from plans to launch compounded oral semaglutide and has committed to never offering compounded Lilly GLP-1 medications. According to the announcement, Hims & Hers never previously offered compounded versions of Lilly's drugs.
The Price of Transformation
The transition from high-margin compounded drugs to lower-margin branded products has proven financially costly. Hims & Hers posted a $92 million loss in Q1 2026, including $33 million in restructuring costs, followed by an $86 million loss in Q2 2026 that included $81 million in one-time costs related to exiting the compounded GLP-1 business. This contrasts sharply with Q2 2025, when the company reported $43 million in profit.
The Eli Lilly deal mirrors the company's March 2025 partnership with Novo Nordisk, which began selling Wegovy and Ozempic through the Hims & Hers platform. Notably, Novo Nordisk had previously sued Hims & Hers over compounded versions of its medications before pivoting to partnership.
Implications for Digital Health and Pharma
The agreements signal a shift in how pharmaceutical manufacturers view telehealth platforms—moving from litigation targets to distribution partners. For Eli Lilly and Novo Nordisk, these partnerships expand market reach while maintaining pricing control and clinical oversight, establishing precedent for manufacturer-platform collaboration in the direct-to-consumer space.
For competing telehealth platforms, the deals create pressure to secure similar manufacturer agreements rather than relying on compounded alternatives. However, Hims & Hers' substantial losses demonstrate the margin compression inherent in this business model transformation, raising questions about long-term sustainability.
The integrated platform approach eliminates friction in the prescription-to-delivery process while providing wraparound support services that may improve patient adherence and outcomes compared to traditional pharmacy dispensing alone. Whether this model can achieve profitability while offering competitive pricing remains an open question as digital health platforms position themselves as pharmaceutical distribution channels.
Sources
Companies in this article
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.